Results 1 to 10 of about 4,368,435 (204)

i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists [PDF]

open access: yesNature Communications
The ability to leverage antibodies to agonize disease relevant biological pathways has tremendous potential for clinical investigation. Yet while antibodies have been successful as antagonists, immune mediators, and targeting agents, they are not readily
Matthew G. Romei   +16 more
doaj   +3 more sources

Antibody Engineering for Pursuing a Healthier Future. [PDF]

open access: yesFront Microbiol, 2017
Since the development of antibody-production techniques, a number of immunoglobulins have been developed on a large scale using conventional methods. Hybridoma technology opened a new horizon in the production of antibodies against target antigens of ...
Saeed AF, Wang R, Ling S, Wang S.
europepmc   +3 more sources

Next generation of multispecific antibody engineering. [PDF]

open access: yesAntib Ther, 2023
Multispecific antibodies recognize two or more epitopes located on the same or distinct targets. This added capability through protein design allows these man-made molecules to address unmet medical needs that are no longer possible with single targeting
Keri D   +4 more
europepmc   +2 more sources

Outsmarting Pathogens with Antibody Engineering. [PDF]

open access: yesAnnu Rev Chem Biomol Eng, 2023
There is growing interest in identifying antibodies that protect against infectious diseases, especially for high-risk individuals and pathogens for which no vaccine is yet available. However, pathogens that manifest as opportunistic or latent infections
Qerqez AN, Silva RP, Maynard JA.
europepmc   +2 more sources

Simplifying complex antibody engineering using machine learning. [PDF]

open access: yesCell Syst, 2023
Machine learning is transforming antibody engineering by enabling the generation of drug-like monoclonal antibodies with unprecedented efficiency. Unsupervised algorithms trained on massive and diverse protein sequence datasets facilitate the prediction ...
Makowski EK, Chen HT, Tessier PM.
europepmc   +2 more sources

AI Models for Protein Design are Driving Antibody Engineering. [PDF]

open access: yesCurr Opin Biomed Eng, 2023
Therapeutic antibody engineering seeks to identify antibody sequences with specific binding to a target and optimized drug-like properties. When guided by deep learning, antibody generation methods can draw on prior knowledge and experimental efforts to ...
Chungyoun M, Gray JJ.
europepmc   +2 more sources

Antibody Engineering for Nuclear Imaging and Radioimmunotherapy. [PDF]

open access: yesJ Nucl Med, 2022
Radiolabeled antibodies have become indispensable tools in nuclear medicine. However, the natural roles of antibodies within the immune system mean that they have several intrinsic limitations as a platform for radiopharmaceuticals.
Rodriguez C   +4 more
europepmc   +2 more sources

Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. [PDF]

open access: yesTrends Mol Med, 2023
Agonist antibodies that target immune checkpoints, such as those in the tumor necrosis factor receptor (TNFR) superfamily, are an important class of emerging therapeutics due to their ability to regulate immune cell activity, especially for treating ...
Jhajj HS, Lwo TS, Yao EL, Tessier PM.
europepmc   +2 more sources

Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective. [PDF]

open access: yesAntib Ther, 2022
Targeted cancer therapies using immunotoxins have achieved remarkable efficacy in hematological malignancies. However, the clinical development of immunotoxins is also faced with many challenges like anti-drug antibodies and dose-limiting toxicity issues.
Li M, Mei S, Yang Y, Shen Y, Chen L.
europepmc   +2 more sources

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective. [PDF]

open access: yesAntibodies (Basel), 2021
Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA approvals in the last two years and a projected market value of over $4 billion by 2024. Major advancements in the engineering of these novel cytotoxic drug carriers have
Lucas AT   +3 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy